NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

34.77USD
30 Oct 2014
Price Change (% chg)

$0.26 (+0.75%)
Prev Close
$34.51
Open
$34.31
Day's High
$35.20
Day's Low
$33.50
Volume
22,158
Avg. Vol
221,480
52-wk High
$53.47
52-wk Low
$16.00

NLNK.OQ

Chart for NLNK.OQ

About

NewLink Genetics Corporation operates as a biopharmaceutical company. The Company, based in the United States, is focused on discovering, developing, and commercializing immunotherapeutic products to improve cancer treatment options for patients and physicians. Its HyperAcute cancer immunotherapies aim to treat non-small cell... (more)

Overall

Beta: --
Market Cap (Mil.): $963.14
Shares Outstanding (Mil.): 27.91
Dividend: --
Yield (%): --

Financials

  NLNK.OQ Industry Sector
P/E (TTM): -- 33.49 34.41
EPS (TTM): -1.29 -- --
ROI: -48.12 18.10 17.37
ROE: -54.46 18.76 18.18
Search Stocks

Canadian Ebola vaccine to be tested in Europe, Gabon, Kenya

LONDON - Trials of an experimental vaccine developed by the Canadian government and licensed to NewLink Genetics will begin swiftly in healthy volunteers in Europe, Gabon and Kenya, under a program with funding from the Wellcome Trust.

29 Oct 2014

Canadian Ebola vaccine to be tested in Europe, Gabon, Kenya

LONDON, Oct 29 - Trials of an experimental vaccine developed by the Canadian government and licensed to NewLink Genetics will begin swiftly in healthy volunteers in Europe, Gabon and Kenya, under a programme with funding from the Wellcome Trust.

29 Oct 2014

RPT-Tens of thousands expected to get Ebola vaccines from January - WHO

GENEVA, Oct 21 - Tens of thousands of people in West Africa are expected to begin getting experimental Ebola vaccines from January, but population-wide immunisation is still far off, the World Health Organization (WHO) said on Tuesday.

21 Oct 2014

Tens of thousands expected to get Ebola vaccines from January - WHO

GENEVA, Oct 21 - Tens of thousands of people in West Africa are expected to begin getting experimental Ebola vaccines from January, but population-wide immunisation is still far off, the World Health Organization (WHO) said on Tuesday.

21 Oct 2014

NewLink in $1 billion deal with Roche to develop cancer drug

- NewLink Genetics Corp said it entered into an agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.

20 Oct 2014

UPDATE 1-NewLink in $1 bln deal with Roche to develop cancer drug

Oct 20 - NewLink Genetics Corp said it entered into an agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.

20 Oct 2014

NewLink in $1 bln deal with Roche to develop cancer drug

Oct 20 - NewLink Genetics Corp said it entered into a licensing agreement with Roche Holding AG to develop NewLink's cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.

20 Oct 2014

Human testing begins on NewLink Genetics' Ebola vaccine

- Human testing of an experimental Ebola vaccine developed by the Canadian health agency and licensed to NewLink Genetics Corp has begun, Canadian health minister Rona Ambrose said.

13 Oct 2014

Human testing begins on NewLink Genetics' Ebola vaccine

Oct 13 - Human testing of an experimental Ebola vaccine developed by the Canadian health agency and licensed to NewLink Genetics Corp has begun, Canadian health minister Rona Ambrose said.

13 Oct 2014

GlaxoSmithKline, NewLink working to bring Ebola vaccines online: WHO

GENEVA - Both GlaxoSmithKline and NewLink Genetics are working to boost their capacity to make Ebola vaccines, with a goal of a "very significant increase in scale during the first half of 2015", the World Health Organization said on Wednesday.

01 Oct 2014

Competitors

  Price Change
Astellas Pharma Inc (4503.T) ¥1,638 -7.00
Pfizer Inc. (PFE.N) $29.60 +0.11
Novartis AG (NOVN.VX) CHF87.30 +0.40
Merck & Co., Inc. (MRK.N) $56.24 +0.04
Roche Holding Ltd. (ROG.VX) CHF281.80 +1.70
Abbott Laboratories (ABT.N) $42.87 +0.13
Sanofi SA (SASY.PA) €72.01 +0.86
AstraZeneca plc (AZN.L) 4,498.00p +54.00
GlaxoSmithKline plc (GSK.L) 1,396.50p -2.00
Eli Lilly and Co (LLY.N) $66.06 +0.57

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Directors Deals Ltd.
$12.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks